Exciting news for young PFIC patients in the United States! The U.S. Food and Drug Administration has approved a label expansion for maralixibat. The expanded label includes use in PFIC patients 12 months and older as well as the higher concentration formulation evaluated in the MARCH Phase 3 study. Congratulations to the Mirum Pharmaceuticals team 
Exciting new for PFIC patients in Europe! The European Commission has granted marketing authorization for maralixibat for the treatment of progressive familial intrahepatic cholestasis in patients three months of age and older.
The PFIC Scientific Conference Held Many Great Presentations and Roundtables That Informed Both The Scientific And Patient Communities.
Thanks to Our Amazing Community, the PFIC Network Has Been Able to Follow Through with Scientific and Research Priorities to Start the PFIC Network Research Grant Program by the End of the Year.